Compare AYTU & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | BCG |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | 150 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 32.6M |
| IPO Year | 2015 | N/A |
| Metric | AYTU | BCG |
|---|---|---|
| Price | $2.45 | $2.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | 29.6K | ★ 132.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | $56.15 |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.26 | $1.36 |
| 52 Week High | $3.07 | $3.44 |
| Indicator | AYTU | BCG |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 52.28 |
| Support Level | $2.15 | $1.90 |
| Resistance Level | $2.64 | $2.15 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 1.96 | 40.44 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.